๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Factors associated with voice therapy outcomes in the treatment of presbyphonia

โœ Scribed by Ted Mau; Barbara H. Jacobson; C. Gaelyn Garrett


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
216 KB
Volume
120
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Objectives/Hypothesis:

Age, vocal fold atrophy, glottic closure pattern, and the burden of medical problems are associated with voice therapy outcomes for presbyphonia.

Study Design:

Retrospective.

Methods:

Records of patients seen over a 3โ€year period at a voice center were screened. Inclusion criteria consisted of age over 55 years, primary complaint of hoarseness, presence of vocal fold atrophy on examination, and absence of laryngeal or neurological pathology. Videostroboscopic examinations on initial presentation were reviewed. Voice therapy outcomes were assessed with the American Speechโ€Languageโ€Hearing Association National Outcomes Measurement System scale. Statistical analysis was performed with Spearman rank correlation and ฯ‡^2^ tests.

Results:

Sixtyโ€seven patients were included in the study. Of the patients, 85% demonstrated improvement with voice therapy. The most common type of glottic closure consisted of a slit gap. Gender or age had no effect on voice therapy outcomes. Larger glottic gaps on initial stroboscopy examination and more pronounced vocal fold atrophy were weakly correlated with less improvement from voice therapy. A weak correlation was also found between the number of chronic medical conditions and poorer outcomes from voice therapy.

Conclusions:

The degree of clinicianโ€determined improvement in vocal function from voice therapy is independent of patient age but is influenced by the degree of vocal fold atrophy, glottic closure pattern, and the patient's burden of medical problems. Laryngoscope, 2010


๐Ÿ“œ SIMILAR VOLUMES


Clinical factors associated with outcome
โœ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to